Evoke Pharma Inc. buy klostergang
Start price
20.08.18
/
50%
€26.09
Target price
06.03.19
€37.88
Performance (%)
-51.87%
End price
06.03.19
€12.56
Summary
This prediction ended on 06.03.19 with a price of €12.56. The BUY prediction by klostergang for Evoke Pharma Inc. performed very badly with a performance of -51.87%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Evoke Pharma Inc. | -9.545% | -9.545% | -72.168% | -96.650% |
| iShares Core DAX® | 0.051% | 5.593% | 14.403% | 19.767% |
| iShares Nasdaq 100 | 1.808% | 7.445% | 34.917% | 57.237% |
| iShares Nikkei 225® | 2.181% | 2.815% | 11.116% | 8.873% |
| iShares S&P 500 | 1.040% | 4.975% | 27.631% | 48.786% |
Comments by klostergang for this prediction
In the thread Evoke Pharma Inc. diskutieren
EVOK on track to get their first approval, action date on the application of April 1, 2019
EVOK announced that the FDA has accepted their New Drug Application for Gimoti, a nasal spray intended to help combat the symptoms of diabetic gastroparesis in adult women.
This nasal formulation of metoclopramide is designed to even out the absorption of the drug, helping to promote motility and reduce nausea and vomiting due to food not leaving the stomach quickly.
(Vom Mitglied beendet)